1. Dr. Hsu has played an important role in the phase Ib trial of atezolizumab-based combination therapy in patients with locally advanced or metastatic solid tumors (GO30140). The trial has demonstrated the efficacy and safety of atezolizumab plus bevacizumab (atezo/bev) as first-line therapy for patients with unresectable hepatocellular carcinoma (HCC) [Lee MS, Ryoo BY, Hsu CH et al: Lancet Oncol 2020; 21:808-820]. Dr. Hsu gave the oral presentation of this trial at several international conferences, including 2019 APASL and 2019 ESMO-Asia Meetings. The results of this trial prompt the design and conduction of the pivotal phase III IMbrave150 study, which has led to successful establishment of atezo/bev as a new standard first-line systemic therapy for advanced HCC in 2020.
Dr. Hsu has been actively participating in several early-phase trials exploring new combination therapy for advanced HCC including MORPHEUS-Liver study. In MORPHEUS-Liver study, the combination of tiragolumab, an anti-TIGIT antibody, with atezo/bev has been shown to exhibit promising efficacies in advanced HCC patients [Finn RS, Ryoo BY, Hsu CH et al: Lancet Oncol. 2025 Feb;26(2):214-226.]. The results of this trial prompt the design and conduction of the phase III IMbrave152 trial to investigate tiragolumab plus atezo/bev versus (vs) atezo/bev as first-line therapy for advanced HCC [NCT05904886]. The trial is currently ongoing.

2. Dr. Hsu has been actively involved in multiple multinational phase III trials of anti-PD-1 immune checkpoint inhibitors (ICIs) in esophageal cancer. These studies have revolutionized the landscape of systemic therapy for esophageal cancer by demonstrating (1) anti-PD-1 ICIs as a preferred 2nd-line therapy and (2) the combination of an anti-PD-1 ICI plus chemotherapy as a new standard 1st-line therapy for advanced esophageal cancer [Kojima T,…Hsu CH,…et al: J Clin Oncol. 2020; 38:4138- 48, Kato K,…Hsu CH,…et al: Lancet Oncol 2019;20:1506-17, and Doki Y…Hsu CH, … et al: N Engl J Med 2022;386: 449-62].
Dr. Hsu has played an important role in studying anti-TIGIT therapy in the treatment of esophageal squamous cell carcinoma (ESCC). Dr. Hsu gave the oral presentation of the SKYSCRAPER-08 study, an international multicenter phase III trial, investigating tiragolumab plus chemotherapy vs chemotherapy as first-line systemic therapy for advanced ESCC patients, at 2024 ASCO-GI Symposium [Hsu CH et al: ASCO-GI Symposium 2024; Abstract #245]. He also served as the corresponding author of MORPHEUS-EC trial, which is a randomized phase II trial of tiragolumab plus atezolizumab plus chemotherapy vs atezolizumab plus chemotherapy vs chemotherapy as first-line therapy for advanced ESCC patients, presented at the same 2024 ASCO-GI Symposium [Hsu CH et al: ASCO-GI Symposium: Abstract #324].
Dr. Hsu has led several investigator-initiated phase II trials, conducted at NTU Hospital, exploring the role of anti-PD-1 ICIs as adjuvant and neoadjuvant therapy for locally advanced esophageal cancer patients [Guo JC, …., Hsu CH. Cancer Immunol Immunother. 2024;73(11):230] [Huang TC, …, Hsu CH. 2024 ASCO Annual Meeting Abstract #e16098], and investigating new ICI-based combination therapy in recurrent and metastatic ESCC [Kuo HY, …., Hsu CH. 2022 ASCO-GI Symposium: Abstract #TPS364].

3. Dr. Hsu has been a member of the Executive Committee of the Asia-Pacific Primary Liver Cancer Expert Association (APPLE Association) since 2017, and served as the Secretary General of the APPLE Association between 2019~2024.